-
1
-
-
0035462130
-
From idea to market: the drug approval process
-
Lipsky, M.S. and Sharp, L.K.: From idea to market: the drug approval process. J Am Board Fam Pract 2001, 14:362-367.
-
(2001)
J Am Board Fam Pract
, vol.14
, pp. 362-367
-
-
Lipsky, M.S.1
Sharp, L.K.2
-
2
-
-
0003403775
-
Clinical Pharmacokinetics: Concepts and Applications
-
Lippincott Williams & Wilkins
-
Rowland, M. and Tozer, T.N.: Clinical Pharmacokinetics: Concepts and Applications, Lippincott Williams & Wilkins, 1995.
-
(1995)
-
-
Rowland, M.1
Tozer, T.N.2
-
3
-
-
6944221357
-
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios
-
Williams, J.A. et al.: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004, 32:1201-1208.
-
(2004)
Drug Metab Dispos
, vol.32
, pp. 1201-1208
-
-
Williams, J.A.1
-
4
-
-
0000197885
-
The hemolytic effect of primaquine and related compounds: a review
-
Beutler, E.: The hemolytic effect of primaquine and related compounds: a review. Blood 1959, 14:103-139.
-
(1959)
Blood
, vol.14
, pp. 103-139
-
-
Beutler, E.1
-
5
-
-
0142022251
-
On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers
-
Kalow, W. and Staron, N.: On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Biochem Physiol 1957, 35:1305-1320.
-
(1957)
Can J Biochem Physiol
, vol.35
, pp. 1305-1320
-
-
Kalow, W.1
Staron, N.2
-
6
-
-
0035721949
-
Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy
-
Ingelman-Sundberg, M.: Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001, 250:186-200.
-
(2001)
J Intern Med
, vol.250
, pp. 186-200
-
-
Ingelman-Sundberg, M.1
-
7
-
-
0017599469
-
Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults
-
Yacobi, A. et al.: Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults. Clin Pharmacol Ther 1977, 21:283-286.
-
(1977)
Clin Pharmacol Ther
, vol.21
, pp. 283-286
-
-
Yacobi, A.1
-
8
-
-
0031472588
-
Role of pharmacokinetics and metabolism in drug discovery and development
-
Lin, J.H. and Lu, A.Y.: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997, 49:403-449.
-
(1997)
Pharmacol Rev
, vol.49
, pp. 403-449
-
-
Lin, J.H.1
Lu, A.Y.2
-
9
-
-
0026254621
-
Genotype or Phenotype: the Definition of a Pharmacogenetic Polymorphism
-
Meyer, U.A.: Genotype or Phenotype: the Definition of a Pharmacogenetic Polymorphism. Pharmacogenetics 1991, 1:66-67.
-
(1991)
Pharmacogenetics
, vol.1
, pp. 66-67
-
-
Meyer, U.A.1
-
10
-
-
0035011217
-
Drug disposition: to phenotype or genotype
-
Dickins, M. and Tucker, G.T.: Drug disposition: to phenotype or genotype. Int J Pharm Med 2001, 15:70-73.
-
(2001)
Int J Pharm Med
, vol.15
, pp. 70-73
-
-
Dickins, M.1
Tucker, G.T.2
-
11
-
-
0004037003
-
Applied Biopharmaceutics and Pharmacokinetics
-
Appleton and Lange
-
Shargel, L. and Yu, A.B.C.: Applied Biopharmaceutics and Pharmacokinetics, Appleton and Lange, 1999.
-
(1999)
-
-
Shargel, L.1
Yu, A.B.C.2
-
12
-
-
33745231761
-
Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans
-
Yamashiro, W. et al.: Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006, 34:1247-1254.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 1247-1254
-
-
Yamashiro, W.1
-
13
-
-
0033953714
-
The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma
-
Liggett, S.B.: The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol 2000, 105:S487-S492.
-
(2000)
J Allergy Clin Immunol
, vol.105
-
-
Liggett, S.B.1
-
14
-
-
0036154953
-
A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans
-
Hollt, V.: A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 2002, 12:1-2.
-
(2002)
Pharmacogenetics
, vol.12
, pp. 1-2
-
-
Hollt, V.1
-
15
-
-
0036152705
-
The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine
-
Lotsch, J. et al.: The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002, 12:3-9.
-
(2002)
Pharmacogenetics
, vol.12
, pp. 3-9
-
-
Lotsch, J.1
-
16
-
-
0141538180
-
Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges
-
Johnson, J.A. and Lima, J.J.: Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003, 13:525-534.
-
(2003)
Pharmacogenetics
, vol.13
, pp. 525-534
-
-
Johnson, J.A.1
Lima, J.J.2
-
17
-
-
0036848427
-
Hello Drug Discovery, I am from insilico, take me to your president
-
Smith, D.A.: Hello Drug Discovery, I am from insilico, take me to your president. Drug Discov Today 2002, 7:1080-1081.
-
(2002)
Drug Discov Today
, vol.7
, pp. 1080-1081
-
-
Smith, D.A.1
-
18
-
-
0033996876
-
Clinical trial simulation in drug development
-
Bonate, P.L.: Clinical trial simulation in drug development. Pharm Res 2000, 17:252-256.
-
(2000)
Pharm Res
, vol.17
, pp. 252-256
-
-
Bonate, P.L.1
-
19
-
-
0035424803
-
Modelling and simulation in clinical drug development
-
Rooney, K.F. et al.: Modelling and simulation in clinical drug development. Drug Discov Today 2001, 6:802-806.
-
(2001)
Drug Discov Today
, vol.6
, pp. 802-806
-
-
Rooney, K.F.1
-
20
-
-
32944471001
-
So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics
-
Williams, J.A. et al.: So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol 2006, 46:258-264.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 258-264
-
-
Williams, J.A.1
-
21
-
-
0037812407
-
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience
-
Blesch, K.S. et al.: Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs 2003, 21:195-223.
-
(2003)
Invest New Drugs
, vol.21
, pp. 195-223
-
-
Blesch, K.S.1
-
22
-
-
0034458680
-
Current methodologies used for evaluation of intestinal permeability and absorption
-
Balimane, P.V. et al.: Current methodologies used for evaluation of intestinal permeability and absorption. J Pharmacol Toxicol Methods 2000, 44:301-312.
-
(2000)
J Pharmacol Toxicol Methods
, vol.44
, pp. 301-312
-
-
Balimane, P.V.1
-
23
-
-
0142010701
-
Drug metabolism and drug interactions: application and clinical value of in vitro models
-
Venkatakrishnan, K. et al.: Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 2003, 4:423-459.
-
(2003)
Curr Drug Metab
, vol.4
, pp. 423-459
-
-
Venkatakrishnan, K.1
-
24
-
-
1542344547
-
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors
-
Proctor, N.J. et al.: Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004, 34:151-178.
-
(2004)
Xenobiotica
, vol.34
, pp. 151-178
-
-
Proctor, N.J.1
-
25
-
-
0034807892
-
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus
-
Tucker, G.T. et al.: Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 2001, 18:1071-1080.
-
(2001)
Pharm Res
, vol.18
, pp. 1071-1080
-
-
Tucker, G.T.1
-
26
-
-
0017335453
-
Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance
-
Rane, A. et al.: Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 1977, 200:420-424.
-
(1977)
J Pharmacol Exp Ther
, vol.200
, pp. 420-424
-
-
Rane, A.1
-
27
-
-
0029950964
-
Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics
-
Iwatsubo, T. et al.: Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 1996, 17:273-310.
-
(1996)
Biopharm Drug Dispos
, vol.17
, pp. 273-310
-
-
Iwatsubo, T.1
-
28
-
-
13244287685
-
'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions
-
Rostami-Hodjegan, A. and Tucker, G.: 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discovery Today: Technologies 2004, 1:441-448.
-
(2004)
Drug Discovery Today: Technologies
, vol.1
, pp. 441-448
-
-
Rostami-Hodjegan, A.1
Tucker, G.2
-
29
-
-
0037216664
-
Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations
-
Visser, S.A. et al.: Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther 2003, 304:88-101.
-
(2003)
J Pharmacol Exp Ther
, vol.304
, pp. 88-101
-
-
Visser, S.A.1
-
30
-
-
0034005059
-
Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam
-
Cleton, A. et al.: Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam. Pharm Res 2000, 17:321-327.
-
(2000)
Pharm Res
, vol.17
, pp. 321-327
-
-
Cleton, A.1
-
31
-
-
0031936583
-
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor
-
Cox, E.H. et al.: Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 1998, 284:1095-1103.
-
(1998)
J Pharmacol Exp Ther
, vol.284
, pp. 1095-1103
-
-
Cox, E.H.1
-
32
-
-
0141525465
-
Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol
-
Liu, J. et al.: Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003, 74:372-379.
-
(2003)
Clin Pharmacol Ther
, vol.74
, pp. 372-379
-
-
Liu, J.1
-
33
-
-
0038433342
-
A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization
-
Bezzina, C.R. et al.: A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 2003, 59:27-36.
-
(2003)
Cardiovasc Res
, vol.59
, pp. 27-36
-
-
Bezzina, C.R.1
-
34
-
-
0035553086
-
Drug target pharmacogenomics: an overview
-
Johnson, J.A.: Drug target pharmacogenomics: an overview. Am J Pharmacogenomics 2001, 1:271-281.
-
(2001)
Am J Pharmacogenomics
, vol.1
, pp. 271-281
-
-
Johnson, J.A.1
-
35
-
-
0037421590
-
Pharmacogenomics-drug disposition, drug targets, and side effects
-
Evans, W.E., McLeod, H.L.: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
-
(2003)
N Engl J Med
, vol.348
, pp. 538-549
-
-
Evans, W.E.1
McLeod, H.L.2
-
36
-
-
33745130722
-
Prediction of in vivo drug clearance from in vitro data I: impact of inter-individual variability
-
Howgate, E.M. et al.: Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 2006, 36:473-497.
-
(2006)
Xenobiotica
, vol.36
, pp. 473-497
-
-
Howgate, E.M.1
-
37
-
-
33746803672
-
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children
-
Johnson, T.N. et al.: Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006, 45:931-956.
-
(2006)
Clin Pharmacokinet
, vol.45
, pp. 931-956
-
-
Johnson, T.N.1
-
38
-
-
34250663402
-
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and Warfarin as an example
-
in press
-
Dickison, G.L. et al.: The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and Warfarin as an example. Brit J Clin Pharmacol 2007, in press.
-
(2007)
Brit J Clin Pharmacol
-
-
Dickison, G.L.1
-
39
-
-
33846450220
-
Clinical trial simulation of the effect of CYP2D6 polymorphism on the antitussive response to dextromethorphan
-
Dickinson, G.L. et al.: Clinical trial simulation of the effect of CYP2D6 polymorphism on the antitussive response to dextromethorphan. J PharmSci 2007, 47:175-186.
-
(2007)
J PharmSci
, vol.47
, pp. 175-186
-
-
Dickinson, G.L.1
-
40
-
-
2942717008
-
Estimation of standard liver volume for liver transplantation in the Korean population
-
Yu, H.C. et al.: Estimation of standard liver volume for liver transplantation in the Korean population. Liver Transpl 2004, 10:779-783.
-
(2004)
Liver Transpl
, vol.10
, pp. 779-783
-
-
Yu, H.C.1
-
41
-
-
33745181651
-
Prediction of in vivo drug clearance from in vitro data II: potential inter-ethnic differences
-
Inoue, S. et al.: Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 2006, 36:499-513.
-
(2006)
Xenobiotica
, vol.36
, pp. 499-513
-
-
Inoue, S.1
-
42
-
-
0036914221
-
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
-
Scordo, M.G. et al.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002, 72:702-710.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 702-710
-
-
Scordo, M.G.1
-
43
-
-
0037374422
-
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
-
Takahashi, H. et al.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003, 73:253-263.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 253-263
-
-
Takahashi, H.1
-
44
-
-
1542346414
-
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
-
Kamali, F. et al.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004, 75:204-212.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 204-212
-
-
Kamali, F.1
-
45
-
-
17944366735
-
Interindividual variability in sensitivity to warfarin-nature or nurture?
-
Loebstein, R. et al.: Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 2001, 70:159-164.
-
(2001)
Clin Pharmacol Ther
, vol.70
, pp. 159-164
-
-
Loebstein, R.1
-
46
-
-
0842308834
-
Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin
-
Khan, T. et al.: Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004, 124:348-354.
-
(2004)
Br J Haematol
, vol.124
, pp. 348-354
-
-
Khan, T.1
-
47
-
-
3042575861
-
Warfarin dosing and cytochrome P450 2C9 polymorphisms
-
Joffe, H.V. et al.: Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004, 91:1123-1128.
-
(2004)
Thromb Haemost
, vol.91
, pp. 1123-1128
-
-
Joffe, H.V.1
-
48
-
-
1842475297
-
Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients
-
Siguret, V. et al.: Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients. Rev Med Interne 2004, 25:271-274.
-
(2004)
Rev Med Interne
, vol.25
, pp. 271-274
-
-
Siguret, V.1
-
49
-
-
0036194038
-
The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin
-
Tabrizi, A.R. et al.: The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002, 194:267-273.
-
(2002)
J Am Coll Surg
, vol.194
, pp. 267-273
-
-
Tabrizi, A.R.1
-
50
-
-
11244284872
-
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism
-
King, B.P. et al.: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004, 14:813-822.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 813-822
-
-
King, B.P.1
-
51
-
-
1542346407
-
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy
-
Peyvandi, F. et al.: CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004, 75:198-203.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 198-203
-
-
Peyvandi, F.1
-
52
-
-
0033694203
-
Genetic modulation of oral anticoagulation with warfarin
-
Margaglione, M. et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000, 84:775-778.
-
(2000)
Thromb Haemost
, vol.84
, pp. 775-778
-
-
Margaglione, M.1
-
53
-
-
0037012465
-
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
-
Higashi, M.K. et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama 2002, 287:1690-1698.
-
(2002)
Jama
, vol.287
, pp. 1690-1698
-
-
Higashi, M.K.1
-
54
-
-
28144454744
-
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations
-
Lindh, J.D. et al.: Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 2005, 78:540-550.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 540-550
-
-
Lindh, J.D.1
-
55
-
-
23044440450
-
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
-
Sconce, E.A. et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106:2329-2333.
-
(2005)
Blood
, vol.106
, pp. 2329-2333
-
-
Sconce, E.A.1
-
56
-
-
33645849823
-
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements
-
Aquilante, C.L. et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006, 79:291-302.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 291-302
-
-
Aquilante, C.L.1
|